Insect Cell Lines Market Analysis

  • Report ID: 5339
  • Published Date: Oct 20, 2023
  • Report Format: PDF, PPT

Insect Cell Lines Market Analysis

Product Type (Sf9, Sf21, High Five, S2)

The high-five segment in the insect cell lines market is estimated to gain a robust revenue share of 40% in the coming years impelled by the rising prevalence of autoimmune disorders. For instance, more than 3% of the world's population suffers from at least one autoimmune illness. It is expected that air pollution, infections, personal lifestyles, stress, and climate change are likely contributing factors to the sharp rise in autoimmune illnesses that are occurring in many regions of the world. The examination of autoimmune-mediated responses has benefited greatly from the use of recombinant proteins that are employed in the creation of biotherapeutic medications. These factors are expected to drive the demand for high-five insect cell lines.

An insect cell line called High Five (BTI-Tn-5B1-4) was developed from the ovarian cells of the cabbage looper which have been extensively studied for the synthesis of heterologous proteins. Moreover, the High Five cell line, the BTI-Tn5B1-4 insect cell line encourages the production of larger concentrations of recombinant proteins that are proteins encoded by recombinant DNA that are created through the introduction of particular genes into hosts, such as bacteria or yeast. According to current estimates, the global prevalence of autoimmune illnesses is increasing by over 7% yearly.

Besides this, the Sf9 segment  in the insect cell lines market is poised to gain a significant revenue share. Sf9 insect cell lines is a clonal strain obtained from the parental Spodoptera frugiperda cell line IPLB-Sf-21-AE, and it is frequently employed in insect cell culture for the manufacture of recombinant proteins.

Application (Biopharmaceutical Manufacturing, Tissue Culture & Engineering, Gene Therapy, Cytogenetic)

Insect cell lines market from biopharmaceutical manufacturing segment is set to garner a notable share shortly. Biopharmaceuticals, or medications derived from live organisms or their cells, are highly effective in treating a variety of ailments and are manufactured by biosynthesis generally that produce proteins and nucleic acids. Moreover, recombinant DNA technology is used to create biopharmaceuticals, which use a host cell to express and secrete therapeutic proteins that can be utilized as medicines, vaccines, and diagnostic tools.

Insect cells can effectively express recombinant proteins and are typically employed for the creation of virus-like particles and vaccines have been widely employed in recent years to produce many kinds of physiologically active recombinant proteins as a cell line retains favorable growth and productivity characteristics.

End-User (Pharmaceuticals, Research Laboratories, Pathology Labs)

The pharmaceuticals manufacturing segment in the insect cell lines market is anticipated to garner a notable share during the forecast timeframe. Pharmaceutical manufacturing is the process of creating pharmaceutical medications on an industrial scale and includes physical procedures such as blending, compression, filtration, heating, encapsulating, shearing, coating, and drying.

The most often utilized insect cell lines are High Five, Sf9, and S2 are often used for the production of vaccines and other biologicals and provide several technological benefits over mammalian cells. Moreover, it has previously been suggested that the preferred biosecurity technique for vaccine manufacture, especially for upcoming influenza pandemic vaccines, is the insect cell expression system as they are capable of carrying out many of the post-translational modifications that viral antigens frequently need.

Our in-depth analysis of the global insect cell lines market includes the following segments:

          Product Type

  • Sf9
  • Sf21
  • High Five
  • S2

          Application

  • Biopharmaceutical Manufacturing
  • Tissue Culture & Engineering
  • Gene Therapy
  • Cytogenetic

          End-User

  • Pharmaceuticals
  •  Research Laboratories
  • Pathology Labs
 
Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 5339
  • Published Date: Oct 20, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The increasing production of vaccines and the rising need for insect-derived products are the major factors driving the growth of the market.

The market size of insect cell lines is anticipated to attain a CAGR of 12% over the forecast period, i.e., 2024 - 2036.

The major players in the market are Sigma-Aldrich Corporation, GE Healthcare Technologies Inc., Lonza Group, Becton, Dickinson & Company, HiMedia Laboratories LLC, Takara Bio Inc., CellGenix GmbH, Atlanta Biologicals Inc., PromoCell GmbH.

The high five segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in the North American region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample